Notes

Slide Show

Outline

1	Your Diagnostics Partner February 2008
2	Safe Harbor
3	Company Overview Strength in Diversity
4	Company Overview Aligned Interests • Nasdaq: TRIB (IPO 1992) • Headquarters - Dublin, Ireland Low sustainable corporate tax rate Management own 12% equity Market cap - US$156 million
5	Diagnostic Industry Overview
6	Growth Objectives & Strategy
7	Sales and Marketing Strategy
8	Company Overview Revenue by Product Group
9	Clinical Lab – Clinical Chemistry
10	Clinical Lab - Haemostasis
11	Clinical Lab - Infectious Diseases
12	Point of Care Tests
13	Point of Care Tests Uni-Gold™ Recombigen^® HIV • FDA Approved • CLIA waived • 10 minute test time • 3^rd Generation Technology • 100% sensitivity • 99.7% specificity
14	HIV POC Test Market Africa •30 million HIV infected in Sub-Saharan Africa 12 million Africans tested with Trinity Biotech products - 2007 Number 2 Brand •Sustainable funding Presidents Emergency Plan for AIDS Relief Global Fund to Fight AIDS TB & Malaria •60%+ gross margin U.S. •1.2 million HIV infected in U.S. 280,000 unaware 40,000 new infections annually •Sustainable funding New: 2007 Presidential Rapid HIV Testing Initiative CDC $35m HIV Prevention Initiative All Americans 13 – 64 No Pre-test counselling No separate written consent •80% gross margin
15	TRIstat™
16	Income Statement 2007
17	Balance Sheet Positioned for Growth
18	Growth Drivers
19	Management Profile Ronan O’Caoimh – Chairman Ronan O’Caoimh (51), co-founded Trinity in 1992 and acted as CFO until 1994 when he became CEO. Prior to joining Trinity, Mr. O’Caoimh was Managing Director of Noctech Limited, an Irish diagnostics company. He holds a Bachelor of Commerce degree from University College, Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.
20	POC HIV Test Comparison
21	3^rd Generation Differentiation – Earlier HIV Detection Capability